Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

16. September 2021 02:45 ET | Quelle: MacroGenics, Inc.

MacroGenics Announces Clinical Results from Cohort A Part 1 of Phase 2/3 MAHOGANY Study of Margetuximab in Combination with Retifanlimab in Gastroesophageal Adenocarcinoma at ESMO 2021

21 of 40 patients (53%) achieved confirmed responses by independent review, exceeding prespecified futility boundary for trial; enrollment proceeding to Part 2 of Cohort A78% of patients had tumor...
07. September 2021 16:30 ET | Quelle: MacroGenics, Inc.

MacroGenics Announces Final Overall Survival Results from SOPHIA Study of MARGENZA™ in Patients with HER2-Positive Metastatic Breast Cancer

Final overall survival (OS) analysis did not demonstrate a statistically significant advantage for MARGENZA over trastuzumabOS was greater with MARGENZA plus chemotherapy in exploratory subgroups of...
25. Januar 2021 07:30 ET | Quelle: MacroGenics, Inc.

MacroGenics Announces Publication of SOPHIA Trial Results for MARGENZA™ in JAMA Oncology

Primary endpoint of Phase 3 study met with MARGENZA (margetuximab-cmkb) showing a 24% Progression Free Survival (PFS) relative risk reduction compared to Herceptin® (trastuzumab), both with...